Ozempic in India: Availability and Price Guide

GLP-1 medications have transformed obesity and diabetes care in the United States and Europe. The same drugs are now becoming more widely available in India, though access, pricing, and the patient experience are meaningfully different.

Here is a practical overview for patients in India.

What GLP-1 medications are available in India?

Availability below is as of October 2026 and changes often.

Ozempic (semaglutide injection) - Available

Novo Nordisk launched Ozempic in India on 12 December 2025 for adults with type 2 diabetes. It comes as a once-weekly FlexTouch pen in 0.25 mg, 0.5 mg and 1 mg doses (the 2 mg dose used in some other countries is not sold in India). Ozempic is not approved for weight loss in India. Novo Nordisk has also partnered with other companies, such as Emcure (brand Poviztra), to widen distribution.

Prescribed by: Endocrinologists, diabetologists, and some internal medicine specialists Available through: Hospital pharmacies, larger chemist chains, and online platforms including 1mg, PharmEasy (in select cities)

Generic semaglutide - Available since March 2026

Semaglutide's patent protection in India ended in March 2026, and many Indian companies launched their own semaglutide brands from 20–21 March 2026, including Dr Reddy's (Obeda), Sun Pharma (Sematrinity for diabetes, Noveltreat for weight management), Glenmark (Glipiq), Natco (Semanat), Alkem and Zydus. Some are pens and some are vials. They contain the same active ingredient as Ozempic and Wegovy, but doses, devices and approved uses differ by brand, so check with your doctor and pharmacist before switching.

Mounjaro (tirzepatide) - Available

Eli Lilly launched Mounjaro in India in 2025. It is approved by CDSCO for type 2 diabetes and for chronic weight management in adults with obesity (BMI 30 or more), or overweight (BMI 27 or more) with at least one weight-related condition. The KwikPen has been available in all doses since August 2025. Cipla also markets tirzepatide under the brand Yurpeak.

Wegovy (semaglutide for weight management) - Available

Wegovy launched in India in June 2025 for weight management. It is a different brand from Ozempic, with higher maintenance doses (up to 2.4 mg weekly).

Saxenda (liraglutide) - Limited

Saxenda, an older daily-injection GLP-1 drug, is not widely available in India. Some generic liraglutide products are sold, mainly for diabetes; ask your doctor or pharmacist what is available.

Rybelsus (oral semaglutide) - Available

Rybelsus is available in India for type 2 diabetes. It is a daily oral tablet, started at 3 mg and increased to 7 mg or 14 mg.

How much do GLP-1 drugs cost in India?

Prices change often, especially since generic semaglutide arrived. These are the published figures we could confirm, with their dates:

Your pharmacy price may differ. Even at lower prices, GLP-1 therapy can be out of reach for many patients without insurance coverage or significant personal income. Buy only from licensed pharmacies with a prescription: fake and unapproved GLP-1 products have been sold online in India.

Does insurance cover GLP-1 drugs in India?

Coverage varies considerably. Some policies may cover diabetes medicines, but reimbursement for weight management use is much less common. Check your specific policy terms.

Finding a doctor

GLP-1 prescriptions in India typically come from:

• Endocrinologists: for diabetes and obesity both
• Diabetologists: for type 2 diabetes
• Bariatric physicians: for obesity management
• Some internal medicine specialists

In smaller cities and towns, access to specialists can be a practical challenge. Telemedicine platforms based in India, including Practo, 1mg Consult, and Apollo247, now offer endocrinology consultations that may be able to provide prescriptions for appropriate patients.

Eating an Indian diet on GLP-1 medications

GLP-1 medications work alongside any dietary pattern, but Indian diets have some characteristics worth keeping in mind.

Protein intake

Traditional Indian diets often derive protein from dal, legumes, paneer, curd, and eggs. GLP-1 drugs reduce total food intake, which can inadvertently reduce protein intake. Many dietitians suggest around 1.2–1.5 g of protein per kg of body weight daily for people losing weight on GLP-1 medicines; ask your doctor or dietitian what is right for you, especially if you have kidney disease. Dal with rice is a good foundation, but higher-protein snacks, Greek curd, paneer, sprouted legumes, eggs, help hit the target when portions are smaller.

Carbohydrate-heavy meals

Rice, roti, paratha, and idli are staples for millions. On GLP-1 therapy, these higher-carbohydrate foods are fine in smaller portions. Large portions can still raise post-meal blood sugar, and may worsen fullness or nausea. Pairing them with protein and vegetables helps blunt this effect.

Nausea triggers

Spicy and oily foods are more likely to trigger or worsen nausea, especially in the early weeks of GLP-1 therapy. During the adjustment period, lighter, milder meals often help.

Hydration

Staying hydrated is important with GLP-1 drugs, especially in hot Indian summers and if you have vomiting or diarrhoea, as dehydration can affect the kidneys. Many adults need around 2–3 litres of fluid daily, but ask your doctor if you have heart or kidney disease.

What to discuss with your doctor in India

Before starting:

• Which drug is appropriate, semaglutide vs tirzepatide, injection vs oral
• The starting dose and titration plan
• How to get consistent supply in your city
• Blood sugar monitoring if you have or are at risk of diabetes
• Thyroid history (GLP-1 drugs carry a warning about thyroid tumour risk and should not be used if you or a family member has had medullary thyroid carcinoma, or if you have MEN 2)
• Pregnancy plans and contraception (semaglutide should be stopped at least 2 months before a planned pregnancy; tirzepatide can make the contraceptive pill less reliable after starting and after each dose increase)
• Other diabetes medicines, especially insulin or sulfonylureas, which raise the risk of low blood sugar

Seek urgent medical help if you have severe stomach pain that does not go away (sometimes spreading to your back, with or without vomiting), or vomiting or diarrhoea that stop you keeping fluids down.

Related Articles

• Obeda Price in India (2026): Full Cost Breakdown
• Is Obeda 60% Cheaper Than Ozempic?
• Obeda vs Ozempic vs Wegovy: What's the Difference?

Final takeaway

Ozempic, Wegovy, Mounjaro, Rybelsus and many generic semaglutide brands are available in India with a prescription, though access and pricing are significantly different from the US and Europe. As of October 2026, published monthly prices range from about ₹1,300 for some generic semaglutide to over ₹16,000 for the highest Wegovy dose. The medications work well alongside Indian diets, but protein intake and hydration need attention. If you are considering GLP-1 therapy in India, an endocrinologist is the right starting point.

Consult your healthcare provider before starting any medication.

Sources

• Ozempic prescribing information (US): https://www.novo-pi.com/ozempic.pdf
• Wegovy prescribing information (US): https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf
• BioSpectrum India — Novo Nordisk launches Ozempic in India (12 December 2025): https://biospectrumindia.com/news/16/27058/novo-nordisk-launches-worlds-most-prescribed-glp-1-drug-ozempic-in-india.html
• Indian Pharma Post — Novo Nordisk India Ozempic and Wegovy prices from 1 April 2026: https://www.indianpharmapost.com/news/lite/novo-nordisk-india-sets-patient-centred-price-of-rs-202day-for-starting-dose-of-ozempic-and-wegovy-19502
• ThePrint — generic semaglutide launches and prices in India (21 March 2026): https://theprint.in/india/rs-325-4200-month-dr-reddys-sun-pharma-glenmark-kick-off-generic-semaglutide-price-war/2885525/
• BioSpectrum India — Eli Lilly launches Mounjaro KwikPen in India (15 August 2025): https://biospectrumindia.com/news/16/26538/eli-lilly-launches-mounjaro-kwikpen-to-advance-care-for-adults-with-type-2-diabetes-and-obesity-in-india.html
• Reuters via MarketScreener — Lilly and Novo in India's obesity drug market, Wegovy June 2025 launch, Yurpeak and Poviztra (December 2025): https://www.marketscreener.com/news/lilly-novo-lock-horns-in-india-s-obesity-drug-race-ce7e59dad98af027
• Medical Dialogues — counterfeit and unapproved tirzepatide seized in Delhi (April 2026): https://medicaldialogues.in/news/industry/pharma/fake-mounjaro-scam-unapproved-toneup-tirzepatide-shots-sold-via-indiamart-169631
• Central Drugs Standard Control Organisation (CDSCO): https://cdsco.gov.in/opencms/opencms/en/Home/
• MedicalDialogues — India semaglutide market and brand launch context: https://medicaldialogues.in/news/industry/pharma/indias-semaglutide-market-set-for-generic-boom-as-patents-expire-over-50-brands-lined-up-for-launch-see-full-list-165838